Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Early-Stage Hodgkin Risk Calculator

A rule-based classifier for favorable versus unfavorable stage I-II classical Hodgkin lymphoma.

Evidence-based context for fast calculator use

Purpose:
Support risk-adapted early Hodgkin treatment discussion
Population:
Stage I-II classical Hodgkin lymphoma
Factors:
Mediastinal bulk, Nodal areas, ESR, B symptoms, Extranodal disease, Age
Reference:
GHSG, EORTC/LYSA, and NCCN early-stage Hodgkin risk definitions
HomeEarly-Stage Hodgkin Lymphoma Risk
Pin your most used calculators here by clicking the star in the dropdown.

Early-Stage Hodgkin Lymphoma Risk

mm/h
years

Clinical Context & Background

Early-stage classical Hodgkin lymphoma is commonly divided into favorable and unfavorable groups to guide chemotherapy and radiation strategy. GHSG, EORTC/LYSA, and NCCN definitions overlap but are not identical.
This tool classifies stage I-II disease using the selected system and shows which unfavorable factors are present. It is a treatment-planning aid only; final management should use the current local guideline, PET response, histology, fertility/cardiopulmonary considerations, and lymphoma specialist judgment.
Formula Logic
Unfavorable if any selected-system unfavorable factor is present; otherwise favorable.

Reference Data

SystemUnfavorable Factors Summarized
GHSGLarge mediastinal mass, extranodal disease, >2 nodal areas, or ESR >50 without B symptoms / >30 with B symptoms
EORTC/LYSALarge mediastinal mass, age >=50, >=4 nodal areas, or ESR >50 without B symptoms / >30 with B symptoms
NCCNBulky mediastinal or >10 cm disease, B symptoms, ESR >50, or >3 disease sites

Share This Calculator

Share:

Popular Tools

Myeloma Master Panel (R2-ISS & Frailty)Febrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

Why do GHSG, EORTC, and NCCN sometimes disagree?

The systems use overlapping but different cutoffs for nodal sites, bulky mediastinum, age, extranodal disease, B symptoms, and ESR. Use the system specified by the protocol or guideline being followed.

Does favorable risk mean no treatment is needed?

No. Favorable risk describes a lower-risk stage I-II group for risk-adapted therapy planning; treatment still depends on guideline context and PET response.

Evidence-based oncology decision support. Verify with clinical guidelines.